Firstly, we used the Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling and Interactive Analysis (GEPIA) databases to systematically analyze the mRNA level of TRPM2 in different types of tumors and assessed its prognostic value using the Kaplan–Meier plotter and the GEPIA database. This evidence concerns the gene TRPM2 and neoplasm.